Read + Share
Deng L, Li Z, Zhang H, Huang H, et al. Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma:
A phase 2, multicenter, open-label study. Am J Hematol 2023 Aug 30. doi: 10.1002/ajh.27064.
PMID: 37647123
|
 |
|
Deng L, Li Z, Zhang H, Huang H, et al. Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma:
A phase 2, multicenter, open-label study. Am J Hematol 2023 Aug 30. doi: 10.1002/ajh.27064.
PMID: 37647123
|
|
|
|